КЛИНИЧЕСКИЕ АССОЦИАЦИИ КОРОНАВИРУСНОЙ ИНФЕКЦИИ COVID-19 И АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ: ПАТОГЕНЕТИЧЕСКИЕ МЕХАНИЗМЫ И ДИСКУССИОННЫЕ ВОПРОСЫ ПРИМЕНЕНИЯ ИНГИБИТОРОВ РЕНИН-АНГИОТЕНЗИН-АЛЬДОСТЕРОНОВОЙ СИСТЕМЫ



DOI: http://dx.doi.org/10.25298/2221-8785-2020-18-4-349-357


Л. В. Якубова, Л. В. Кежун, В. А. Снежицкий

Аннотация


Обзор современных публикаций свидетельствует, что у пациентов с артериальной гипертензией (АГ) повышен риск тяжелого течения и смертельного исхода COVID-19. К основным патогенетическим механизмам, объясняющим ассоциацию АГ с COVID-19, относят влияние коронавируса на работу ренин-ангиотензин-альдостероновой системы (РААС), которая участвует в развитии и прогрессировании АГ. В обзоре представлены результаты ряда исследований с оценкой влияния применения иАПФ/БРА у пациентов с сердечно-сосудистыми заболеваниями на развитие и течение COVID-19. Результаты международного анализа данных показали, что использование иАПФ/БРА у пациентов с АГ и COVID-19 ассоциированы с меньшими показателями общей смертности, а использование иАПФ, статинов и женский пол связаны с большей вероятностью выживания пациентов. Представлены данные по перспективным разработкам новых лекарственных
средств, влияющих на работу РААС.

Ключевые слова


COVID-19; артериальная гипертензия; ренин-ангиотензин-альдостероновая система

Полный текст:

Литература


Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 / J. D. Stanaway [et al.] // Lancet. – 2018. – Vol. 392, iss. 10159. – P. 1923-1994. – doi: 10.1016/S0140-6736(18)32225-6.

Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-based Studies from 90 Countries / K. T. Mills [et al.] // Circulation. – 2016. – Vol. 134, iss. 6. – P. 441-450. – doi: 10.1161/ CIRCULATIONAHA.115.018912.

Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review / S. P. Adhikari [et al.] // Infectious Diseases of Poverty. – 2020. – Vol. 9, iss. 1. – P. 29. – doi: 10.1186/ s40249-020-00646-x.

Sifuentes-Rodríguez, E. COVID-19: The outbreak caused by a new coronavirus / E. Sifuentes-Rodríguez, D. Palacios-Reyes // Boletin medico del Hospital Infantil de Mexico. – 2020. – Vol. 77, iss. 2. – P. 47-53. – doi: 10.24875/BMHIM.20000039.

The SARS-CoV-2 outbreak: what we know / D. Wu [et al.] // International Journal of Infectious Diseases. – 2020. – Vol. 94. – P. – 44-48. – doi: 10.1016/j.ijid.2020.03.004.

Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19 / R. Kreutz [et al.] // Cardiovascular Research. – 2020. – cvaa097. – doi: 10.1093/cvr/cvaa097.

Potential Effects of Coronaviruses on the Cardiovascular System: A Review / M. Madjid [et al.] // JAMA. Cardiology. – 2020. – doi: 10.1001/jamacardio.2020.1286.

Status of hypertension in China: results from the China Hypertension Survey, 2012-2015 / Z. Wang [et al.] // Circulation. – 2018. – Vol. 137, iss. 22. – P. 2344-2356. – doi: 10.1161/CIRCULATIONAHA.117.032380.

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China / S. Bai [et al.] // Zhonghua Liu Xing Bing Xue Za Zhi. – 2020. – Vol. 41, iss. 2. – P. 145-151. – doi: 10.3760/cma.j.issn.0254-6450.2020.02.003.

Singh, A. K. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers / A. K. Singh, R. Gupta, A. Misra // Diabetology & Metabolic Syndrome. – 2020. – Vol. 14, iss. 4. – P. 283-287. – doi: 10.1016/j. dsx.2020.03.016.

Clinical characteristics of coronavirus disease 2019 in China / W. Guan [et al.] // New England Journal of Medicine. – 2020. – № 382. – P. 1708-1720. – doi: 10.1056/NEJMoa2002032.

Clinical characteristics of 140 patients infected by SARSCoV-2 in Wuhan, China / J.-j. Zhang [et al.] // Allergy. – 2020. – Jul 75(7). – P. 1730-1741. – doi: 10.1111/ all.14238.

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1-30, 2020 / S. Garg [et al.] // Morbidity and Mortality Weekly Report. – 2020. – Vol. 69, iss.15. – P. 458-464. – doi: 10.15585/mmwr.mm6915e3.

Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database / G. Tocci [et al.] // Journal of Human Hypertension. – 2017. – Vol. 31, iss. 4. – P. 258-262. – doi: 10.1038/jhh.2016.71.

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area / S. Richardson [et al.] // JAMA. – 2020. – Vol. 323, iss. 20. – P. 2052-2059. – doi: 10.1001/ jama.2020.6775.

Paul, M. Physiology of local renin-angiotensin systems / M. Paul, A. P. Mehr, R. Kreutz // Physiological Reviews. – 2006. – Vol. 86, iss. 3. – P. 747-803. doi: 10.1152/ physrev.00036.2005.

Romero, C. Novel RAAS agonists and antagonists: clinical applications and controversies / C. Romero, M. Orias, M. Weir // Nature Reviews Endocrinology. – 2015. – Vol. 11, iss. 4. – P. 242-252. – doi: 10.1038/nrendo.2015.6.

Ferrario, C. M. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease / C. M. Ferrario, A. E. Mullick // Pharmacology Research. – 2017. – Vol. 125, (pt. A). – P. 57-71. – doi: 10.1016/j.phrs.2017.05.020.

Якубова, Л. В. Изменение активности ренина плазмы и функции эндотелия у лиц с артериальной гипертензией при терапии с включением ингибитора ангиотензинпревращающего фермента и холекальциферола / Л. В. Якубова, Л. В. Кежун, О. В. Семячкина-Глушковская // Рецепт. – 2017. – Т. 20, № 6. – С. 568-577.

Кежун, Л. В. Роль ренин-ангиотензин-альдостероновой системы и витамина D в развитии артериальной гипертензии у женщин в перименопаузальном периоде / Л. В. Кежун, Л. В. Янковская // Журнал Гродненского государственного медицинского университета. – 2013. – № 1 (41). – С. 14-17.

Кежун, Л. В. Активность ренина плазмы функции эндотелия и статус витамина D женщин с артериальной гипертензией в пременопаузальном и раннем постменопаузальном периодах / Л. В. Кежун, Л. В. Янковская // Журнал Гродненского государственного медицинского университета. – 2014. – № 4 (48). – С. 37-42. 22.

Angiotensin receptors: distribution, signaling and function / D. T. Dihn [et al.] // Clinical Science. – 2001. – Vol. 100, iss. 5. – Р. 481-492.

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensinconverting enzyme 2 / C. M. Ferrario [et al.] // Circulation. – 2005. – Vol. 111, iss. 20. – P. 2605-2610. – doi:10.1161/ CIRCULATIONAHA.104.510461.

New frontiers in the intrarenal Renin-Angiotensin system: a critical review of classical and new paradigms / J. L. Zhuo [et al.] // Frontiers in Endocrinology (Lausanne). – 2013. – Vol. 4. – P. 166. – doi: 10.3389/fendo.2013.00166.

Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS / Y. Wan [et al.] // Journal of Virology. – 2020. – doi: 10.1128/JVI.00127-20.

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury / K. Kuba [et al.] // Nature Medicine. – 2005. – Vol. 11, iss. 8. – P. 875-879. – doi: 10.1038/nm1267.

Imai, Y. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice / Y. Imai, K. Kuba, J. M. Penninger // Experimental physiology. – 2008. – Vol. 93, iss. 5. – P. 543-548. – doi: 10.1113/ expphysiol.2007.040048.

Channappanavar, R. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology / R. Channappanavar, S. Perlman // Seminars in Immunopathology. – 2017. – Vol. 39, iss. 5. – P. 529-539. – doi: 10.10 07/s0 0281-017-0629-x.

Tveito, K. Cytokine storms in COVID-19 cases / K. Tveito // Tidsskrift for den Norske Legeforening. – 2020. – P. 140. – doi: 10.4045/tidsskr.20.0239.

Activation of human T cells in hypertension: studies of humanized mice and hypertensive humans / H. A. Itani [et al.] // Hypertension. – 2016. – Vol. 68, iss. 1. – P. 123-132. doi: 10.1161/HYPERTENSIONAHA.116.07237.

Hypertension and increased endothelial mechanical stretch promote monocyte differentiation and activation: roles of STAT3, interleukin 6 and hydrogen peroxide / R. Loperena [et al.] // Cardiovascular Research. – 2018. – Vol. 114, iss. 11. – P. 1547-1563. – https://doi.org/10.1093/cvr/cvy112.

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19 / G. Mancia [et al.] // New England Journal of Medicine. – 2020. – Vol. 382. – P. 2431-2440. – doi: 10.1056/NEJMoa2006923.

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19 / H. Reynolds [et al.] // New England Journal of Medicine. 2020. – Vol. 382. – P. 2441-2448. – doi: 10.1056/NEJMoa2008975.

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 / M. R. Mehra [et al.] // New England Journal of Medicine. – 2020. – Vol. 382. – P. e102. – doi: 10.1056/ NEJMoa2007621.

ACE2 gene expression is activated in human heart failure / A. B. Goulter [et al.] // BMC. Medicine. – 2004. – Vol. 2. – P. 19. – doi: 10.1186/1741-7015-2-19.

Circulating plasma concentrations of angiotensinconverting enzyme 2 in men and women with heart failure and effects of renin angiotensin-aldosterone inhibitors / I. E. Sama [et al.] // European Heart Journal. – 2020. – Vol. 41 (19). – P. 1810-1817. – doi:10.1093/eurheartj/ ehaa373.

Onder, G. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy / G. Onder, G. Rezza, S. Brusaferro // JAMA. – 2020. – Vol. 323, iss. 18. – P. 1775-1776. – doi: 10.1001/jama.2020.4683.

Angiotensin-converting enzyme2 (ACE2) as a SARSCoV-2 receptor: molecular mechanisms and potential therapeutic target / H. Zhang [et al.] // Intensive Care Medicine. – 2020. – Vol. 46 (4). – P. 586-590. – doi: 10.1007/s00134-020-05985-9.

Coronavirus disease 2019 (COVID-19): do angiotensinconverting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect / R. Sommerstein [et al.] // Journal of the American Heart Association. – 2020. – Vol. 9, iss. 7. – P. e016509. – doi:10.1161/JAHA.120.016509.

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 / V. Monteil [et al.] // Cell. – 2020. – Vol. 181, iss. 4. – P. 905-913. – doi: 10.1016/j.cell.2020.04.004.

Novel therapeutic approaches targeting the reninangiotensin system and associated peptides in hypertension and heart failure / L. B. Arendse [et al.] // Pharmacological Reviews. – 2019. – № 71 (4). – P. 539-570. – doi: 10.1124/ pr.118.017129.

Immune mechanisms of hypertension / G. Drummond [et al.] // Nature Reviews Immunology. – 2019. – Vol. 19, iss. 8. – P. 517-532. – doi: 10.1038/s41577-019-0160-5.

Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment [Electronic resource] / China NHCotPsRo. – 7th ed. – 2020. – Mode of access: http:// kjfy.meetingchina.org/msite/news/show/cn/3337.html. – Date of access: 22.05.20.

IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis / C.-H. Chou [et al.] // Cardiovascular Research. – 2018. – Vol. 114, iss. 5. – P. 690-702. – doi: 10.1093/cvr/cvy013.

Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (covid-19) [Electronic resource] / B. Diao [et al.] // MedRxiv. – 2020. – Mode of access: www.medrxiv.org/content/10.1101/2020.02.18. 20024364v1. – Date of access: 22.15.20. – doi:10.1101/20 20.02.18.20024364.

White blood cells and blood pressure: A Mendelian Randomization Study / M. Siedlinski [et al.] // Circulation. – 2020. – 2020. – Vol. 141, iss. 16. – P. 1307-1317. – doi:10.1161/CIRCULATIONAHA.119.045102.

Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician: Statement [Electronic resource] / American Heart Association, Heart Failure Society of America, American College of Cardiology // Newsroom. – Mode of access: https://newsroom.heart.org/ news/patients-takingace-i-and-arbs-who-contract-covid-19-should-continuetreatment-unless-otherwise-advised-by-their-physician. – Date of access: 20.05.20.

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid 19 / M. Vaduganathan [et al.] // New England Journal of Medicine. – 2020. – Vol. 382, iss. 17. – P. 1653-1659. – doi: 10.1056 / NEJMsr2005760.

Angiotensin II Receptor Blockers and AngiotensinConverting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension [Electronic resource] / Y. Guang [et al.] // MedRxiv. – 2020. – Mode of access: www.medrxiv.org/content/10.1101/2020.03.31. 20038935v1.full.pdf+html. – Date of access: 22.05.20. – https://doi.org/10.1101/2020.03.31.20038935.

Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19 / P. Zhang [et al.] // Circulation Research. – 2020. – Vol. 126, iss. 12. – P. 1671-1681. – doi: 10.1161/CIRCRESAHA.120.317134.


Ссылки

  • На текущий момент ссылки отсутствуют.